Revelation Biosciences (REVB) announced safety and activity data for its Phase 1b PRIME clinical study in stage 3 and 4 chronic kidney disease patients. The primary endpoint to evaluate the safety and ...

SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained ...

"I would like to thank all those that have voted for the December 3, 2025, Special Meeting and remind all those who have not yet voted to vote," said James Rolke, Chief Executive Officer, Revelation.

PARIS, France—(UPDATED) A small, randomized trial may breathe new life into the concept of using a drug-coated balloon (DCB) instead of a stent in acute MI, particularly in younger patients with ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Revelation Biosciences ( (REVB)) has ...

SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize ...